HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction (Q66073799)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction |
clinical trial |
Statements
A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease (English)
0 references
24 February 2016
0 references
30 November 2017
0 references
600
0 references